Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening.

Publication ,  Journal Article
DelFavero, JJ; Jnah, AJ; Newberry, D
Published in: Neonatal network : NN
August 2020

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy worldwide, is an insufficient amount of the G6PD enzyme, which is vital to the protection of the erythrocyte. Deficient enzyme levels lead to oxidative damage, hemolysis, and resultant severe hyperbilirubinemia. If not promptly recognized and treated, G6PD deficiency can potentially lead to bilirubin-induced neurologic dysfunction, acute bilirubin encephalopathy, and kernicterus. Glucose-6-phosphate dehydrogenase deficiency is one of the three most common causes for pathologic hyperbilirubinemia. A change in migration patterns and intercultural marriages have created an increased incidence of G6PD deficiency in the United States. Currently, there is no universally mandated metabolic screening or clinical risk assessment tool for G6PD deficiency in the United States. Mandatory universal screening for G6PD deficiency, which includes surveillance and hospital-based risk assessment tools, can identify the at-risk infant and foster early identification, diagnosis, and treatment to eliminate neurotoxicity.

Duke Scholars

Published In

Neonatal network : NN

DOI

EISSN

1539-2880

ISSN

0730-0832

Publication Date

August 2020

Volume

39

Issue

5

Start / End Page

270 / 282

Related Subject Headings

  • United States
  • Risk Assessment
  • Practice Guidelines as Topic
  • Neonatal Nursing
  • Mass Screening
  • Male
  • Infant, Newborn
  • Humans
  • Glucosephosphate Dehydrogenase Deficiency
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DelFavero, J. J., Jnah, A. J., & Newberry, D. (2020). Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening. Neonatal Network : NN, 39(5), 270–282. https://doi.org/10.1891/0730-0832.39.5.270
DelFavero, Julie Jensen, Amy J. Jnah, and Desi Newberry. “Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening.Neonatal Network : NN 39, no. 5 (August 2020): 270–82. https://doi.org/10.1891/0730-0832.39.5.270.
DelFavero JJ, Jnah AJ, Newberry D. Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening. Neonatal network : NN. 2020 Aug;39(5):270–82.
DelFavero, Julie Jensen, et al. “Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening.Neonatal Network : NN, vol. 39, no. 5, Aug. 2020, pp. 270–82. Epmc, doi:10.1891/0730-0832.39.5.270.
DelFavero JJ, Jnah AJ, Newberry D. Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening. Neonatal network : NN. 2020 Aug;39(5):270–282.

Published In

Neonatal network : NN

DOI

EISSN

1539-2880

ISSN

0730-0832

Publication Date

August 2020

Volume

39

Issue

5

Start / End Page

270 / 282

Related Subject Headings

  • United States
  • Risk Assessment
  • Practice Guidelines as Topic
  • Neonatal Nursing
  • Mass Screening
  • Male
  • Infant, Newborn
  • Humans
  • Glucosephosphate Dehydrogenase Deficiency
  • Female